These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19181641)

  • 1. Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events.
    Miner MM
    Mayo Clin Proc; 2009 Feb; 84(2):102-4. PubMed ID: 19181641
    [No Abstract]   [Full Text] [Related]  

  • 2. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
    Gazzaruso C
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):173-80. PubMed ID: 16509813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?
    Fonseca V; Jawa A
    Am J Cardiol; 2005 Dec; 96(12B):13M-18M. PubMed ID: 16387560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erectile dysfunction in patients with diabetes mellitus].
    Mazo EB; Gamidov SI; Ovchinnikov RI; Iremashvili VV
    Ter Arkh; 2005; 77(11):88-92. PubMed ID: 16404870
    [No Abstract]   [Full Text] [Related]  

  • 5. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
    Nehra A
    Mayo Clin Proc; 2009 Feb; 84(2):139-48. PubMed ID: 19181648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of erectile dysfunction in chronic renal disease patients on conservative treatment.
    Mesquita JF; Ramos TF; Mesquita FP; Bastos Netto JM; Bastos MG; Figueiredo AA
    Clinics (Sao Paulo); 2012; 67(2):181-3. PubMed ID: 22358245
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
    Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
    Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile dysfunction in the cardiac patient.
    Kloner RA
    Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
    Solomon H; Wierzbicki AS; Lumb PJ; Lambert-Hammill M; Jackson G
    Am J Hypertens; 2006 Sep; 19(9):915-9. PubMed ID: 16942933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.
    Vicari E; La Vignera S; Condorelli R; Calogero AE
    J Sex Med; 2010 Mar; 7(3):1247-53. PubMed ID: 19674252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
    DeBusk RF
    Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking erectile dysfunction and coronary artery disease.
    Rodriguez JJ; Al Dashti R; Schwarz ER
    Int J Impot Res; 2005 Dec; 17 Suppl 1():S12-8. PubMed ID: 16391538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of tadalafil for the treatment of erectile dysfunction].
    Liu ZY; Sun YH
    Zhonghua Nan Ke Xue; 2008 Apr; 14(4):377-80. PubMed ID: 18481436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
    Ganz P
    Am J Cardiol; 2005 Dec; 96(12B):8M-12M. PubMed ID: 16387559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
    Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
    Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile dysfunction: when to treat and when to refer.
    Randrup ER; Baum N
    Geriatrics; 2004 Nov; 59(11):48-50, 52. PubMed ID: 15615160
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
    Kloner RA; Montorsi P; DeBusk RF
    J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835
    [No Abstract]   [Full Text] [Related]  

  • 19. ERECTILE DYSFUNCTION AS A PREDICTOR OF CARDIOVASCULAR DISEASE.
    Janjgava S; Doliashvili T
    Georgian Med News; 2016 Dec; (261):36-41. PubMed ID: 28132040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating men's health holistically: protecting endothelial function early.
    Cardiovasc J Afr; 2008; 19(4):230. PubMed ID: 18776975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.